Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus

Fig. 7

a MYCN western blot after 18 h of treatment with increasing concentrations of MP1 (0.1 μM, 0.25 μM, 0.50 μM, 1.0 μM) in BE-2c cells. Increased cleaved PARP indicative of apoptosis/necrosis, decreased MCL-1 and MYCN protein expression, and increased LC3II (lower band) indicative of stimulation of autophagy with all values normalized using total protein. b BRD-4, BCL2, and BAX protein reported after normalization using cyclophilin loading controls. MYCN reported as mean ± SD of 6 experiments, MCL-1 as mean ± SD of 4 experiments, cleaved PARP as mean ± SD of 3 experiments, and LC3II/LC3I as mean ± SD of 3 experiments. BRD4, BCL2, and BAX reported as mean ± SD of 3 experiments c Ratio of treatment (DMSO control, MP1 0.1 µM, 0.25 µM, 0.5 µM, and 1.0 µM) to media control for MYCN, MCL-1, cleaved PARP, LC3II/I, bcl-2, BAX, and BRD-4 proteins

Back to article page
\